In a phase II study reported in the Journal of Clinical Oncology, Khodadoust et al found that pembrolizumab was active in patients with advanced relapsed or refractory mycosis fungoides or Sézary syndrome.
In a study reported in the Journal of Clinical Oncology, Rosenwald et al found that MYC rearrangement was associated with poorer outcomes in diffuse large B-cell lymphoma (DLBCL) when accompanied by rearrangement of BCL2 and/or BCL6 and an immunoglobulin translocation partner gene.
As reported in the Journal of Clinical Oncology by Fuchs et al, final results of the German Hodgkin Study Group phase III HD16 trial in early-stage favorable Hodgkin lymphoma indicate that combined modality therapy (CMT) is associated with better progression-free survival vs chemotherapy alone among patients with negative positron-emission tomography (PET) findings after two cycles of chemotherapy (PET-2). PET-2 positivity was associated with poorer progression-free survival among all patients receiving CMT.
Primary central nervous system (CNS) lymphoma is a rare type of non-Hodgkin lymphoma in which standards of care have not been well established...